-transparent.png){kind=logo}
The tumoricidal activity of magnetically responsive albumin microspheres tagged with either doxorubicin or Staphylococcal protein A was tested against an induced mammary adenocarcinoma, 13762, implanted subcutaneously in the tail of female Fischer-344 rats. Magnetically responsive albumin microspheres containing Fe3O4 particles were prepared by an emulsion polymerization method incorporating either doxorubicin or protein A into the albumin matrix. Microspheres were produced with an average diameter of 1 micron (0.2 to 1.5 micron) in a concentration of 10(9) microspheres/mg. Microspheres were injected either directly into the tail artery and localized to the implanted tumor using a permanent bipolar adjustable gap magnet with a field strength of 8000 Oe, or directly into the femoral vein with no magnetic localization. Control groups consisted of animals treated with intravenously or intraarterially administered microspheres containing no active agent, and a no-treatment group. Survival was significantly greater in both the doxorubicin- and protein A-treated animals than in the control groups. First appearance of local metastases was prolonged in only the intraarterial magnetically localized doxorubicin-treated group of animals. Tumor growth rate was significantly depressed in both intraarterially magnetically localized treatment groups when compared to intravenously administered nonlocalized treatment groups. Magnetically responsive albumin microspheres appear to be an effective delivery system for cytotoxic agents and biologic response modifiers. Significant tumoricidal activity can be produced with a one-time administration of these agents utilizing this drug delivery system.
M A Rettenmaier, and
J A Stratton, and
M L Berman, and
A Senyei, and
K Widder, and
D B White, and
P J DiSaia
January 1985,
Methods in enzymology,
M A Rettenmaier, and
J A Stratton, and
M L Berman, and
A Senyei, and
K Widder, and
D B White, and
P J DiSaia
August 1981,
Gynecologic oncology,
M A Rettenmaier, and
J A Stratton, and
M L Berman, and
A Senyei, and
K Widder, and
D B White, and
P J DiSaia
October 1980,
Cancer research,
M A Rettenmaier, and
J A Stratton, and
M L Berman, and
A Senyei, and
K Widder, and
D B White, and
P J DiSaia
May 1991,
Journal of orthopaedic research : official publication of the Orthopaedic Research Society,
M A Rettenmaier, and
J A Stratton, and
M L Berman, and
A Senyei, and
K Widder, and
D B White, and
P J DiSaia
September 2020,
IET nanobiotechnology,
M A Rettenmaier, and
J A Stratton, and
M L Berman, and
A Senyei, and
K Widder, and
D B White, and
P J DiSaia
January 1988,
Life sciences,
M A Rettenmaier, and
J A Stratton, and
M L Berman, and
A Senyei, and
K Widder, and
D B White, and
P J DiSaia
March 2010,
Journal of nanoscience and nanotechnology,
M A Rettenmaier, and
J A Stratton, and
M L Berman, and
A Senyei, and
K Widder, and
D B White, and
P J DiSaia
February 1992,
Anti-cancer drugs,
M A Rettenmaier, and
J A Stratton, and
M L Berman, and
A Senyei, and
K Widder, and
D B White, and
P J DiSaia
December 2020,
Nanomaterials (Basel, Switzerland),
M A Rettenmaier, and
J A Stratton, and
M L Berman, and
A Senyei, and
K Widder, and
D B White, and
P J DiSaia
July 1981,
Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
